Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction

Crit Care Med. 2009 Oct;37(10):2746-52. doi: 10.1097/CCM.0b013e3181ab858a.

Abstract

Objectives: To test early measurement of human leukocyte antigen-DR expression on circulating monocytes (mHLA-DR) as prognostic marker, and the trend of mHLA-DR recovery for the prediction of late secondary infection risk in a large intensive care unit population.

Design: Prospective, observational study over 16 mos.

Setting: Intensive care unit in a tertiary teaching hospital.

Inclusion criteria: Simplified Acute Physiology Score II >15, age >18 yrs.

Measurements and main results: The mHLA-DR was measured by flow cytometry within the first 3 days and twice a week until discharge. We used a logistic regression model for outcome prediction, and a competing risk approach to test the relationship between mHLA-DR recovery (log (mHLA-DR) slope) and incidence of secondary infection. A total of 283 consecutive patients suffering from various pathologies were monitored (Simplified Acute Physiology Score II = 39, Sepsis-related Organ Failure Assessment of 5 on day 0). Early mHLA-DR was decreased in the whole population, however, more deeply in sepsis (p < .0001). Low mHLA-DR was associated with mortality in the whole population (p = .003), as in subgroups (nonseptic, neurologic, and septic), but not when adjusted on Simplified Acute Physiology Score II. In patients with a length of stay of >7 days (n = 70), the lower the slope of mHLA-DR recovery, the higher the incidence of the first secondary infection (adjusted on early mHLA-DR, p = .04).

Conclusions: For a given severity, mHLA-DR proved not to a predictive marker of outcome, but a weak trend of mHLA-DR recovery was associated with an increased risk of secondary infection. Monitoring immune functions through mHLA-DR in intensive care unit patients therefore could be useful to identify a high risk of secondary infection.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Infections / immunology*
  • Bacterial Infections / mortality
  • Bacterial Infections / therapy
  • Cross Infection / immunology*
  • Cross Infection / mortality
  • Cross Infection / therapy
  • Drug Therapy, Combination
  • Female
  • HLA-DR Antigens / blood*
  • Hospital Mortality
  • Humans
  • Immune Tolerance / immunology
  • Immunization, Passive
  • Intensive Care Units*
  • Length of Stay / statistics & numerical data
  • Male
  • Middle Aged
  • Monocytes / immunology*
  • Multiple Organ Failure / immunology
  • Multiple Organ Failure / mortality
  • Multiple Organ Failure / therapy
  • Pneumonia, Ventilator-Associated / immunology
  • Pneumonia, Ventilator-Associated / mortality
  • Predictive Value of Tests
  • Prognosis
  • Reference Values
  • Risk Factors
  • Shock, Septic / immunology*
  • Shock, Septic / mortality
  • Shock, Septic / therapy
  • Systemic Inflammatory Response Syndrome / immunology*
  • Systemic Inflammatory Response Syndrome / mortality
  • Systemic Inflammatory Response Syndrome / therapy

Substances

  • Anti-Bacterial Agents
  • HLA-DR Antigens